Cantor Fitzgerald Reiterates “Overweight” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports.

Other equities analysts have also recently issued research reports about the company. Oppenheimer assumed coverage on MoonLake Immunotherapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $104.00 price objective for the company. Wolfe Research downgraded shares of MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a research note on Monday, August 26th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday, September 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.45.

MoonLake Immunotherapeutics Stock Down 2.1 %

Shares of MLTX stock opened at $54.26 on Monday. MoonLake Immunotherapeutics has a 12 month low of $35.11 and a 12 month high of $64.98. The company has a market cap of $3.47 billion, a PE ratio of -72.35 and a beta of 1.26. The business’s 50 day moving average is $47.04 and its two-hundred day moving average is $44.85.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.11). During the same quarter last year, the business posted ($0.23) EPS. As a group, equities analysts expect that MoonLake Immunotherapeutics will post -1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at $51,000. Bellevue Group AG acquired a new stake in shares of MoonLake Immunotherapeutics in the first quarter valued at approximately $221,000. PNC Financial Services Group Inc. raised its position in MoonLake Immunotherapeutics by 50.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,147 shares of the company’s stock worth $371,000 after purchasing an additional 2,067 shares during the last quarter. DNB Asset Management AS lifted its stake in shares of MoonLake Immunotherapeutics by 29.8% during the second quarter. DNB Asset Management AS now owns 7,372 shares of the company’s stock valued at $324,000 after acquiring an additional 1,694 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter worth approximately $726,000. 93.85% of the stock is owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.